Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

McArthur, 2013, Targeting oncogenic drivers and the immune system in melanoma, J Clin Oncol, 31, 499, 10.1200/JCO.2012.45.5568 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Ascierto, 2012, The role of BRAF V600 mutation in melanoma, J Transl Med, 10, 85, 10.1186/1479-5876-10-85 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Blank, 2004, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res, 64, 1140, 10.1158/0008-5472.CAN-03-3259 Okazaki, 2007, PD-1 and PD-1 ligands: from discovery to clinical application, Int Immunol, 19, 813, 10.1093/intimm/dxm057 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Hochberg, 1988, A sharper Bonferroni procedure for multiple tests of significance, Biometrika, 75, 800, 10.1093/biomet/75.4.800 Efron, 1977, The efficacy of Cox's likelihood function for censored data, J Am Stat Assoc, 72, 557, 10.1080/01621459.1977.10480613 Miettinen, 1985, Comparative analysis of two rates, Stat Med, 4, 213, 10.1002/sim.4780040211 Schoenfeld, 1982, Partial residuals for the proportional hazards regression model, Biometrika, 69, 239, 10.1093/biomet/69.1.239 Uno, 2014, Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis, J Clin Oncol, 32, 2380, 10.1200/JCO.2014.55.2208 Robert, 2014, CTLA4 blockade broadens the peripheral T-cell receptor repertoire, Clin Cancer Res, 20, 2424, 10.1158/1078-0432.CCR-13-2648 Cha, 2014, Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients, Sci Transl Med, 6, 238ra70, 10.1126/scitranslmed.3008211 Kvistborg, 2014, Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Sci Transl Med, 6, 254ra128, 10.1126/scitranslmed.3008918 Huang, 2011, CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans, Clin Cancer Res, 17, 4101, 10.1158/1078-0432.CCR-11-0407 Robert, 2014, Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes, Oncoimmunology, 3, e29244, 10.4161/onci.29244 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Spranger, 2013, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells, Sci Transl Med, 5, 200ra116, 10.1126/scitranslmed.3006504 Bald, 2014, Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation, Cancer Discov, 4, 674, 10.1158/2159-8290.CD-13-0458 Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 10.1056/NEJMoa1503093